Investigational Drug Information for Losmapimod
What is the development status for investigational drug Losmapimod?
Losmapimod is an investigational drug.
There have been 15 clinical trials for Losmapimod.
The most recent clinical trial was a Phase 3 trial, which was initiated on August 28th 2020.
The most common disease conditions in clinical trials are Muscular Dystrophies, Muscular Dystrophy, Facioscapulohumeral, and Lung Diseases. The leading clinical trial sponsors are GlaxoSmithKline, Fulcrum Therapeutics, and The TIMI Study Group.
There are two hundred and three US patents protecting this investigational drug and eight hundred and seventy-six international patents.
Summary for Losmapimod
| US Patents | 203 |
| International Patents | 876 |
| US Patent Applications | 545 |
| WIPO Patent Applications | 176 |
| Japanese Patent Applications | 23 |
| Clinical Trial Progress | Phase 3 (2020-08-28) |
| Vendors | 61 |
Recent Clinical Trials for Losmapimod
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) | Fulcrum Therapeutics | Phase 3 |
| Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets | Fulcrum Therapeutics | Phase 1 |
| Losmapimod Safety and Efficacy in COVID-19 | Fulcrum Therapeutics | Phase 3 |
Clinical Trial Summary for Losmapimod
Top disease conditions for Losmapimod
Top clinical trial sponsors for Losmapimod
US Patents for Losmapimod
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Losmapimod | ⤷ Start Trial | Compounds .alpha..sub.v.beta..sub.6 integrin antagonists | GlaxoSmithKline Intellectual Property Development Limited (Brentford, Middlesex, GB) | ⤷ Start Trial |
| Losmapimod | ⤷ Start Trial | IBAT inhibitors for the treatment of liver diseases | Albireo AB (Gothenburg, SE) | ⤷ Start Trial |
| Losmapimod | ⤷ Start Trial | Compounds alpha v beta 6 integrin antagonists | GlaxoSmithKline Intellectual Property Development Ltd | ⤷ Start Trial |
| Losmapimod | ⤷ Start Trial | Inhalable pharmaceutical compositions | iCeutica Pty Ltd. (Iluka, WA, AU) | ⤷ Start Trial |
| Losmapimod | ⤷ Start Trial | Inhibitor of p38 map kinase | Respivert Ltd | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Losmapimod
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Losmapimod | Argentina | AR101995 | 2034-09-26 | ⤷ Start Trial |
| Losmapimod | Australia | AU2015320859 | 2034-09-26 | ⤷ Start Trial |
| Losmapimod | Brazil | BR112017006253 | 2034-09-26 | ⤷ Start Trial |
| Losmapimod | Canada | CA2962326 | 2034-09-26 | ⤷ Start Trial |
| Losmapimod | China | CN107074849 | 2034-09-26 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
